The InFLUenza Patient-Reported Outcome (FLU-PRO) questionnaire was designed to standardize and comprehensively assess symptoms associated with various viral strains across multiple body systems over the course of the disease within and across subgroups. It was developed using qualitative and quantitative methods consistent with scientific measurement standards and US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines for clinical outcome assessments. The questionnaire has been used successfully as a daily symptom diary in studies of influenza, influenza-like illness (ILI), respiratory syncytial virus (RSV) and rhinovirus, and completed by over 4,000 patients between 12-81 years of age with adherence rates over 90%.
This webinar will describe the FLU-PRO and its suitability for evaluating symptoms in clinical trials of COVID-19.
This webinar will:
- Describe the FLU-PRO instrument and the spectrum of symptoms able to be measured
- Provide insight into the type of research questions FLU-PRO can help address
- Outline the benefits and potential challenges of use in COVID studies
- Provide information on how to access and license the instrument